Impact of a Multifaceted Prevention Program on Ventilator-associated Pneumonia Including Selective Oropharyngeal Decontamination
Overview
Authors
Affiliations
Purpose: We describe the impact of a multifaceted program for decreasing ventilator-associated pneumonia (VAP) after implementing nine preventive measures, including selective oropharyngeal decontamination (SOD).
Methods: We compared VAP rates during an 8-month pre-intervention period, a 12-month intervention period, and an 11-month post-intervention period in a cohort of patients who received mechanical ventilation (MV) for > 48 h. The primary objective was to assess the effect on first VAP occurrence, using a Cox cause-specific proportional hazards model. Secondary objectives included the impact on emergence of antimicrobial resistance, antibiotic consumption, duration of MV, and ICU mortality.
Results: Pre-intervention, intervention and post-intervention VAP rates were 24.0, 11.0 and 3.9 VAP episodes per 1000 ventilation-days, respectively. VAP rates decreased by 56% [hazard ratio (HR) 0.44, 95% CI 0.29-0.65; P < 0.001] in the intervention and by 85% (HR 0.15, 95% CI 0.08-0.27; P < 0.001) in the post-intervention periods. During the intervention period, VAP rates decreased by 42% (HR 0.58, 95% CI 0.38-0.87; P < 0.001) after implementation of eight preventive measures without SOD, and by 70% after adding SOD (HR 0.30, 95% CI 0.13-0.72; P < 0.001) compared to the pre-intervention period. The incidence density of intrinsically resistant bacteria (to colistin or tobramycin) did not increase. We documented a significant reduction of days of therapy per 1000 patient-days of broad-spectrum antibiotic used to treat lower respiratory tract infection (P < 0.028), median duration of MV (from 7.1 to 6.4 days; P < 0.003) and ICU mortality (from 16.2 to 13.5%; P < 0.049) for patients ventilated > 48 h between the pre- and post-intervention periods.
Conclusions: Our preventive program produced a sustained decrease in VAP incidence. SOD provides an additive value.
Bijarania S, Kaur R, Biswal M, Maheshwar S, Ganesan R, Puri G Infect Prev Pract. 2025; 7(1):100423.
PMID: 39807390 PMC: 11728882. DOI: 10.1016/j.infpip.2024.100423.
Hurley J Antibiotics (Basel). 2024; 13(4).
PMID: 38666992 PMC: 11047347. DOI: 10.3390/antibiotics13040316.
Wen X, Cheng M, Song Z, Hu J, Liang X, Lang W Biomed Rep. 2024; 20(2):32.
PMID: 38273899 PMC: 10809323. DOI: 10.3892/br.2024.1720.
Martinez-Reviejo R, Tejada S, Jansson M, Ruiz-Spinelli A, Ramirez-Estrada S, Ege D J Intensive Med. 2023; 3(4):352-364.
PMID: 38028633 PMC: 10658042. DOI: 10.1016/j.jointm.2023.04.004.
Semet C Infect Prev Pract. 2023; 5(4):100320.
PMID: 38028359 PMC: 10663678. DOI: 10.1016/j.infpip.2023.100320.